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Tuberculosis remains a major health problem throughout the world causing large number of deaths. Eﬀective disease control and
eradication programs require the identiﬁcation of major antigens recognized by the protective responses against M. tuberculosis.
In this study, we have investigated humoral and cellular immune responses to M. tuberculosis-speciﬁc Ag85A, Ag85B, and ESAT-6
antigens in Brazilian patients with pulmonary (P, n = 13) or extrapulmonary (EP, n = 12) tuberculosis, patients undergoing
chemotherapy (PT, n = 23), and noninfected healthy individuals (NI, n = 7). Compared to NI, we observed increased levels
of IgG1 responses to Ag85B and ESAT-6 in P and PT groups. Regarding cellular immunity, Ag85A and ESAT-6 were able to
discriminate P, PT, and EP patients from healthy individuals by IFN-γ production and P and PT groups from EP individuals
by production of TNF-α. In summary, these ﬁndings demonstrate the ability of Ag85A, Ag85B, and ESAT-6 to diﬀerentiate TB
patients from controls by IgG1, IFN-γ and TNF-α production.
1.Introduction
Tuberculosis (TB) remains the largest single infectious
cause of death globally. It is estimated that 30% of the
word population is infected with Mycobacterium tuberculosis
resulting in approximately 2-3 million deaths each year [1].
Further,theAIDSepidemicandtheappearanceofmultidrug
resistant strains of M. tuberculosis have contributed to
the reemergence of TB in developing countries; however,
this disease continues to be a devastating entity in the
developing world [2]. At present, the only registered vaccine
against tuberculosis, Mycobacterium bovis Bacillus Calmette-
Gu´ erin (BCG), was introduced in 1921 and has been widely
used;ho wev er ,itseﬀectivenessremainscontroversialbecause
their protection levels are extremely variable in diﬀerent
population [3–5]. Furthermore, vaccination with M. bovis
BCG is contraindicated in immunocompromised subjects,
including acquired immunodeﬁciency syndrome patients,
who are usually at a very high risk of developing TB [6]. In
addition, the diagnostic value of the presently used skin test
reagent, puriﬁed protein derivative (PPD) of Mycobacterium
tuberculosis, is low, owing to cross-reactivity with environ-
mental mycobacteria and vaccine strains of M. bovis BCG [7,
8].Thus,theeﬀectivecontrolanderadicationofTBisdepen-
dent upon the availability of eﬀective vaccines and reagents
for speciﬁc diagnosis. For this purpose, the identiﬁcation2 Clinical and Developmental Immunology
of major antigens recognized by the protective immune
response against M. tuberculosis remains a critical step.
Among M. tuberculosis antigens studied, the 30/32KDa
antigen 85 (Ag85) complex has been the focus of intense
research over the past several years and comprises three
closely related proteins, 85A (32KDa), 85B (30KDa), and
85C (32.5KDa) that possess enzymatic mycolyl-transferase
activity[9–11]. The Ag85 complex induces protective immu-
nity against TB in guinea pigs [12], and strong proliferation
and IFN-γ production in peripheral blood mononuclear
cells (PBMC) from healthy tuberculin reactors [13]. Regard-
ing, ESAT-6, the early secreted antigenic target is a low-
molecular-weight protein essentially present in pathogenic
mycobacteria including members of the mycobacterium
complex (M. tuberculosis, M bovis, and M. africanum)a n d
M. leprae [14]. Analysis of T-cell responses to M. tuberculosis
ESAT-6 showed an elevated range of recognition from many
tuberculosis patients [15]. Consequently, the possible use of
ESAT-6 as a marker of M. tuberculosis infection has been
proposed. Moreover, other studies have demonstrated the
ability of this protein to discriminate tuberculosis patients
fromhealthdonorsinahighendemicarea[16].Additionally,
ESAT-6 is able to diﬀerentiate tuberculosis patients from
both BCG-vaccinated individuals and M. avium infected
patients [17].
The main goal of this study was to evaluate the cellular
and humoral immune responses to the recombinant pro-
teins Ag85A, Ag85B, and ESAT-6 in Brazilian pulmonary
and extra-pulomary tuberculosis patients and individuals
undergoing chemotherapy. The recombinant proteins were
produced in E. coli and puriﬁed by aﬃnity chromatogra-
phy. Cellular proliferation and cytokine production were
evaluated in peripheral blood mononuclear cells (PBMC)
and speciﬁc antibody isotypes to Ag85A, Ag85B and ESAT-
6 were measured in serum of TB patients and controls. In
this study, we have shown the ability of Ag85B and ESAT-6 to
diﬀerentiate TB patients from controls by IgG1 production.
Additionally, the results here demonstrated that Ag85A and
ESAT-6 were able to discriminate P, PT, and EP patients
from healthy individuals by IFN-γ production and P and PT
groups from EP individuals by production of TNF-α.
2.MaterialsandMethods
2.1. Study Population. Patients with active pulmonary TB
(P, n = 13) or active extra-pulmonary TB (EP, n = 12),
and pulmonary TB patients with 1–3 months of anti-TB
chemotherapy (PT, n = 23), diagnosed at the outpatient unit
of the Oswaldo Cruz Health Center, Belo Horizonte, Minas
Gerais,Brazil,wereenrolledinthisstudy.AllTBpatientshad
sputum-positive bacilloscopy or culture-conﬁrmed disease.
The EP-TB group comprised six pleural TB, ﬁve miliary TB
and one intestinal TB as shown in Table 1. Seven healthy
non-BCG vaccinated individuals (all PPD-) without prior
history of mycobacterial infection were included as control
group. All enrolled patients tested negative by ELISA for
HIV.Noneoftheindividualshadevidenceofacuteinfections
(other than TB) at the time of sample collection. Twenty ml
of blood was taken from each patient.
2.2.EthicsCommittee. Allpatientsgavepermissionforblood
sampling after written consent, and the Ethics Committee
of the Santa Casa Hospital at Belo Horizonte, Minas Gerais,
Brazil approved the research protocol.
2.3.MycobacterialAntigens. TherecombinantAg85A,Ag85B
e ESAT-6 was produced using the pMAL-c2 expression sys-
tem. Brieﬂy, the pMAL-85A, pMAL-85B, or pMAL-ESAT-6
construct was used to transform Escherichia coli DH5α strain
as previously described [18]. Bacterial cells were induced
using 0.42mM IPTG (isopropyl-β-D-thiogalactoside) and
recombinant proteins fused to the maltose binding protein
(MBP) were produced. Three hours after gene expression,
the cells were harvested and lysed using thermal shock,
sonication, and lysozyme treatment. The fusion protein
recovered in the supernatant was then puriﬁed by aﬃnity
chromatography using an amylose resin (New England
BioLabs). Residual endotoxin levels were removed from
recombinant proteins by using Triton X-114 and measured
to be <50EU/mg recombinant protein by the LAL assay
(Limulus amoebocyte lysate). Puriﬁed protein derivative
(PPD-RT50) was obtained from Statens Serum Institute,
Copenhagen, Denmark.
2.4. T Cell Proliferation Assays. Heparinized venous blood
was obtained from all patients and controls, and peripheral
blood mononuclear cells (PBMCs) were isolated by Ficoll-
Hypaque (Ficoll 6,42% (SIGMA) and Hypaque 50% (Sanoﬁ
Synthelab)) density centrifugation. Cells were washed in
RPMI 1640 fresh medium and cultured (2,5×105 cells/well)
in ﬂat-bottom 96-well plates (Nunc Brand Products) in
200μL of RPMI 1640 medium supplemented with 10%
AB + heat-inactivated human serum and 1% antibi-
otic/antimycotic (Gibco-BRL) and incubated at 37◦Ci na
humidiﬁed 5%CO2 incubator with recombinant antigens
or medium alone (control). The recombinant antigens were
titered to determine the optimal protein concentration for
proliferation assays. Ag85A, Ag85B, and PPD was used at
25μg/ml, ESAT-6 at 50μg/ml, and phytohaemagglutinin
(PHA) was used at 10μg/ml. The concentration of the
recombinantantigenstestedherewashighercomparedtothe
used by other authors because we produced the mycobac-
terial antigens fused to MBP that has itself a molecular
mass of approximately 42.6kDa. All antigens were plated
in triplicate. After 3 days (mitogen) or 5 days (antigens)
of incubation, [3H] thymidine (0.5μCi/well) was added to
the cultures. Eighteen hours later, the supernatants were
collected, and the cells were harvested. The incorporated
radioactivity in the cells was evaluated by liquid scintillation
spectroscopy as a measure of cellular proliferation. Mean
counts per minute for triplicate cultures and stimulation
index (SI) were obtained for each patient. The SI was the
ratio of mean counts per minute in the presence of antigen
to means counts per minute in medium alone.
2.5. Cytokine Measurement. Concentration of human IFN-γ,
TNF-α, IL-10, and IL-4 in cell culture supernatants of
proliferation assays was determined by enzyme-linked
immunosorbent assay (ELISA) using kits Duoset from R&DClinical and Developmental Immunology 3
Table 1: Clinical characteristics of TB patients and controls in this study.
Groups No. of subjects TST Males/females Age (mean ± SD) Age range
Non-infected (NI) 7 − 05/02 40.1 ±9.5 28–55
TB patients under treatment (PT)∗ 25 + 14/11 39.8 ±14.6 22–76
Pulmonary TB untreated (P) 13 + 09/04 41.0 ±15.7 19–69
Extra-pulmonary TB (EP) 12 + 08/04 41.1 ±16.5 21–76
(i) Pleural 6
(ii) Miliary 5
(iii) Intestinal 1
∗The treatment consisted of Rifampicin (10–20mg/kg/day), Isoniazide (10–20mg/kg/day), and Piraminazide (30–50mg/kg/day). PT patients were
undergoing 1–3 months of chemotherapy. TST tuberculin skin test.
Systems (Minneapolis, MN, USA) according to manufac-
turer’s directions.
2.6. Detection of Antibody Responses. Detection of antibody
against recombinant Ag85A, Ag85B, and ESAT-6 antigens
in TB patients and healthy individual sera was performed
by a modiﬁed ELISA [19]. Brieﬂy, ninety-six-well ﬂat-
bottom microtiter plates (Nunc, Roskilde, Denmark) were
coated overnight at 4◦C with 100μL of each recombinant
antigen separately at a concentration of 5μg/ml in 0.1M
carbonate bicarbonate buﬀer (pH 9.6) per well. The plates
were then blocked with 10% bovine fetal serum in PBS
(pH 7.4) for 2h at room temperature. Subsequently, the
plates were washed three times with PBS plus 0.05%
Tween-20 (PBS-T20). Serum samples diluted 1:100 in PBS-
T20 (100μL/well) were added in duplicate, and the plates
were incubated for 1h at room temperature. Peroxidase-
labeled anti-IgG (Sigma Chemical Co., St. Louis, MO),
anti-IgM (Sigma), and anti-IgA (Sigma) were added at
dilutions of 1:2,000, 1:2,000, and 1:10,000 (100μL/well),
respectively. After 1h at 37◦C, the plates were washed, and
OPD(orthophenyl-diaminobenzidine)plus0.05%hydrogen
peroxide in phosphate citrate buﬀer (pH 5) was added
(100μL/well). This mixture was then incubated for 30min
at room temperature, and the reaction was stopped by
addition of 5%H2SO4 (50μL/well). Absorbance was read at
492nm using a microplate reader (BioRad, Hercules, CA).
TodetermineIgGsubclasseslevels,thepreviousprotocolwas
slightlymodiﬁed.Theserumdilutionwaschangedto1:80for
IgG1 and IgG3 and 1:20 to IgG2 and IgG4. Diluted sera were
added to the plates, and they were incubated for 2h at 37◦C.
After washing, peroxidase-labeled antihuman antibody was
dispensed in each well at concentrations of 1:1,000 (IgG1,
IgG3) or 1:500 (IgG2, IgG4), and the plates were incubated
for 12–16h at 4◦C. The next steps were identical to those
described above.
2.7. Statistical Analysis. Results are reported as means ±
standard errors. Diﬀerences between responses from TB
patient groups and control groups were analyzed with non-
parametric Kruskall-Wallis test. Correlation between ESAT-
6 induced IFN-γ and proliferation responses from patients
WAS identiﬁed using Spearman Correlation. Statistical anal-
ysis was performed using the GraphPad Prism software
version 5.0 (GraphPad software incorporated). Statistical
diﬀerences were considered signiﬁcant at P<. 05.
3. Results
3.1. IgG1 Is the Predominant Antibody Isotype Present in Sera
of TB Patients. To investigate the presence of speciﬁc anti-
Ag85A, -Ag85B or -ESAT-6 antibodies in sera of TB patients
with diﬀerent clinical forms of the disease, ELISA were
performed. Figure 1 shows the levels of speciﬁc IgG, IgM
and IgA to mycobacterial antigens in sera of TB patients and
healthy donors. The levels of anti-PPD IgG were signiﬁcantly
elevated in all tuberculosis patients compared to NI group.
Furthermore, increased levels of IgG anti-Ag85B and anti-
ESAT-6 were detected in P and PT groups compared to NI
individuals. Interestingly, no signiﬁcant titers of IgG anti-
Ag85A were detected in studied patients. Levels of speciﬁc
IgAantibodiestoallantigenswereverylowanddidnotdiﬀer
between the studied groups. In addition, only marginal anti-
A g 8 5 Ba n da n t i - P P DI g Ml e v e l sw e r eo b s e r v e di nt h ePa n d
PT groups.
Having observed elevated IgG levels to Ag85B and
ESTA-6 antigens in patient sera, we decided to determine
the IgG subclasses involved. The IgG subclass proﬁle of TB
patients was characterized predominantly by IgG1 responses
to rAg85B and rESAT-6 on P and PT groups (Figure 2).
Additionally, statistically signiﬁcant levels of IgG3 to rAg85B,
ESAT-6 and Ag85A were also detected in sera of PT and P
group, however at lower levels. These results demonstrate
the better performance of the Ag85B and ESAT-6 antigens
compared to Ag85A to determine humoral responses in
patients with active TB.
3.2. Proliferative Responses to Mycobacterial Antigens. In
ordertodetermineTcell-reactivitytothemycobacterialanti-
gens tested, lymphoproliferative responses were measured in
cells from tuberculosis patients and healthy individuals. As
shown in Figure 3, proliferative responses upon stimulation
with rESAT-6 were able to discriminate P, EP, and PT
tuberculosis patients from healthy individuals. Regarding
Ag85A and Ag85B, they were able to diﬀerentiate PT
and P tuberculosis patients from noninfected individuals.
Only when PPD was used as antigen, this assay was able
to discriminate PT and P patients from individuals with4 Clinical and Developmental Immunology
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Figure 1: Levels of serum IgG (hatched box), IgM (black box) and IgA (empty box) to Ag85A, Ag85B, ESAT-6, and PPD were determined
in serum of non-infected individuals (NI), pulmonary tuberculosis patients (P), pulmonary tuberculosis patients undergoing treatment
(PT) and extra-pulmonary tuberculosis (EP). Results are presented as mean ± standard deviation. Diﬀerences between responses from TB
patient groups and control groups were analyzed with nonparametric Kruskall-Wallis test. ∗Statistically signiﬁcant diﬀerences in relation to
NI group (P<. 05).
extrapulmonary TB. PBMC of all individuals showed high
cell proliferation after stimulation with PHA as a positive
control (data not shown).
3.3. Cytokine Proﬁle in Response to Recombinant Mycobacte-
rialAntigens. In order to evaluate the cytokines produced by
P, EP, and PT patient cells to the mycobacterial recombinant
antigens, IFN-γ,T N F - α, IL-10 and IL-4 were measured.
Figure 4 shows a signiﬁcant production of IFN-γ after
stimulationwithAg85AandESAT-6inthePTgroup(1285±
1571 and 1355 ± 976, resp.), P group (1268 ± 1722 and
974 ± 218, resp.), and EP group (903 ± 785 and 920 ± 2477,
resp.) in comparison to the non-infected control group. This
elevated production of IFN-γ in ESAT6-stimulated PBMC of
TBpatientscorrelatedwithpositive responsetoESAT6inthe
proliferation assays (Spearman test; PT group r = 0.5158,
P = .0118; P group r = 0.5659, P = .0438; EP group r =
0.6224, P = .0307). Moreover, in response to Ag85B, only PT
(1206 ±2087) and P (1227 ±799) patients produced signiﬁ-
cant levels of IFN-γ compared to healthy individuals. The PT
groups were the higher producers of IFN-γ in response to all
recombinant antigens; however no diﬀerence was observed
within this group among the diﬀerent antigens used. All TB
patientsproducedhighlevelsofIFN-γ toPPD,andthisresult
is in agreement with the complex antigenic mixture of PPD.
RegardingTNF-αproduction,weobservedthatPTand P
groups produced signiﬁcant levels of this cytokine when
stimulated with Ag85A, Ag85B or ESAT-6. However, no
recombinantantigenstestedwereabletoinducegreaterlevels
of TNF-α in EP group compared to healthy individuals.
Furthermore, only Ag85A or ESAT6 antigens induced pro-
duction of higher amounts of TNF-α by PT and P cells that
alloweddiscriminationbetweenthesegroupsfromEPgroup.
Additionally, all patients produced high levels of TNF-α to
PPD.
As for IL-10, a regulatory cytokine, we observed that
the group of TB patients who had initiated chemotherapy
(PT) produced higher amounts of IL-10 compared to P or
EP groups when Ag85A, Ag85B and ESAT-6 were tested.
These values were signiﬁcant to diﬀerentiate PT from P
and EP groups. None of the tested recombinant antigens or
PPD induced detectable production of IL-4 by PBMC of all
individuals tested (data not shown).
4. Discussion
For the development of new vaccines and diagnostic
reagents, there is an urgent need for assessment of immune
responses to M. tuberculosis antigens in areas of TB endemic-
ity. In the present study T-cell and antibody responses to
recombinant Ag85A, Ag85B or ESAT-6 were investigated
in Brazilian patients with pulmonary or extra-pulmonary
TB and patients undergoing treatment compared to non-
infected individuals. Several studies have detected antibodies
inseraofpatientswithactiveTBagainstavarietyofM.tuber-
culosis antigens [20–22]. Herein, patients with active disease
or undergoing >2 months of treatment presented elevated
levels of IgG anti-ESAT-6 and anti-Ag85B but not to Ag85A.
High levels of antibodies against ﬁltered M. tuberculosis
antigens in the ﬁrst two months of chemotherapy have been
associated with intense stimulation of the humoral response
by antigens released from killed bacteria combined with the
disappearance of circulating mycobacterial antigens so that
speciﬁc antibodies are no longer trapped in the immune
complexes [23]. Therefore, large amounts of IgG antibodies
against secreted Ag85B and ESAT-6 antigens appear to be
associated with viable and metabolically active bacilli. Little
attention has been given to the subclasses involved in TB
[24]. In our study, the analysis of IgG subclasses to the
mycobacterial recombinant antigens revealed the predomi-
nance of IgG1 but not IgG2 and IgG4 to ESAT-6 and Ag85B
in sera of patients of the P or PT group. However, we also
detected signiﬁcant levels of IgG3 against Ag85A, Ag85B and
ESAT-6 in these groups of patients. Our results are consistentClinical and Developmental Immunology 5
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Figure 2: Levels of serum IgG1 (a), IgG2 (b), IgG3 (c) and IgG4 (d) to Ag85A, Ag85B, ESAT-6, and PPD were determined in serum of
non-infected individuals (NI), pulmonary tuberculosis patients (P), pulmonary tuberculosis patients undergoing treatment (PT) and extra-
pulmonary tuberculosis (EP). Results are presented as mean ± standard deviation. Diﬀerences between responses from TB patient groups
and control groups were analyzed with nonparametric Kruskall-Wallis test. ∗Statistically signiﬁcant diﬀerences in relation to NI group
(P<. 05).
with other studies that also observed predominance of IgG1
antibodies in the sera of patients with active TB [19, 24,
25]. Since Ag85A and Ag85B share around 77% of amino
acids identity, one could expect them to have common
immunodominant epitopes. Despite pronounced sequence
homology among these Ag85 members, D’Souza et al. [26]
have shown that diﬀerent Ag85-speciﬁc immunodominant
T-cell epitopes were identiﬁed in BALB/c and C57BL/6
mouse strains. These diﬀerences in MHC-restriction during
Ag85A and Ag85B epitope mapping might be one of the
reasons why we did not observed signiﬁcant levels of anti-
Ag85A IgG in our TB patients. Similarly, Van Vooren et al.
[27] suggested that Ag85B was the most useful component
of the Ag85 complex for serodiagnosis of the active form of
TB.
Recently, commercial immunodiagnostic tests for TB
have been introduced. These tests are based on the M.
tuberculosis ESAT-6 and culture ﬁltrate protein 10 (CFP-10)
and include a whole-blood IFN-γ ELISA (QuantiFERON-
TB Gold, Cellestis Ltd, Victoria, Australia) and an ELISPOT
assay (T-SPOT.TB, Oxford Immunotec, Oxfordshire, UK).
Both tests have shown promising results in the detection
of latent TB and the potential use for diﬀerential diagnoses
of active tuberculosis [28, 29]. However, the sensitivities
and speciﬁcities of these assays vary among the diﬀerent
populations studied, due mostly to the diﬀerent HLA
genetic backgrounds, the prevalence of TB infection, and the
coverage of M. bovis BCG vaccination [30]. Furthermore,
there is a need to develop new diagnostic tools to detect
extra-pulmonary TB and sputum negative cases. In our
study, pulmonary or extra-pulmonary TB patients and
individuals undergoing chemotherapy responded to ESAT-
6 as evaluated by lymphoproliferative responses or by IFN-
γ production determined in the supernatants of stimulated6 Clinical and Developmental Immunology
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Figure 3: Lymphocyte proliferation in response to recombinant Ag85A, Ag85B and ESAT-6. Freshly isolated PBMC from non-infected
individuals (NI), pulmonary TB patients (P), pulmonary TB patients in treatment (PT) and extra-pulmonary TB (EP) were cultured in
the presence of Ag85A (25μg/ml), 85B (25μg/ml), PPD (25μg / m l )o rE S A T - 6( 5 0μg/ml) for 5 days and incorporation of [3H] thymidine
was measured. Results are expressed as stimulation index (SI) mean of triplicate cultures. Horizontal bars indicate mean values. Diﬀerences
between responses from TB patient groups and control groups were analyzed with nonparametric Kruskall-Wallis test. (∗) Statistically
signiﬁcant diﬀerences in relation to NI group and (δ) in relation to EP group (P<. 05).
PBMC. Additionally, Ag85A was also recognized by all
TB patient cells compared to non-infected individuals as
measured by IFN-γ secretion. This data demonstrates that
ESAT-6 and Ag85A are recognized by T cell from many
tuberculosis patients undergoing distinct periods of clinical
disease and is consistent with Ulrichs et al. [15] ﬁndings by
which PBMCs from tuberculosis patients, but not healthy
donors, respond to ESAT-6. Furthermore, as described pre-
viously by Antas et al. [31], the Ag85A and Ag85B proteins
were also recognized by PBMC of pulmonary tuberculosis
patients and individuals undergoing treatment measured
by elevated proliferation and IFN-γ production. Regarding
TNF-α, clinical studies have associated the use of TNF-
blockers with progression from latent tuberculosis infection
to disease [32]. Further, Caccamo et al. [33]h a v er e p o r t e d
highpercentageofCD4+TcellsexpressingIFN-γ/IL-2/TNF-
αin active TB patients and it seems to be associated with live
bacterial loads, as indicated by the decrease in frequency of
multifunctional T cells in TB patients after completion of
antimycobacterial therapy. In our study, we have observed
elevated levels of TNF-α to Ag85A, Ag85B, and ESAT-
6 in patients with pulmonary tuberculosis or undergoing
treatment but not in extra-pulmonary TB patients. However,
only Ag85A and ESAT-6 antigens were able to discriminate
PT and P patients from EP. This data might be associated
to diﬀerential production of TNF-α by CD4+, and CD8+ T
cells and the compartmentalization of immune response at
site of disease. Marei et al. [34]d e m o n s t r a t e dad i ﬀerential
expression of IFN-γ and TNF-α in CD4+ T cells and CD8+
T cells after stimulation with ESAT-6. In their study, CD4+
T cells are the main producer of TNF-α while IFN-γ was
producedbyeitherCD4+ orCD8+Tcells.Inaddition, other
studies have provided evidence for compartmentalization of
Th1 cytokines at the site of disease in humans [35, 36]. We
suggest that compartmentalization of the immune response
in EP patients can lead to sequestration of TNF-α producing
cells at the disease site and it contributes to reduced
production of this cytokine in peripheral blood in response
to Ag85A, Ag85B and ESAT-6. Herein, our results suggest
that Ag85A and ESAT-6 are able to diﬀerentiate P, PT and EP
patients from healthy individuals by IFN-γ production and
from P and PT groups to EP individuals by production of
TNF-α. In a recent study, it was reported that similar levels
of cytokine and antibody responses to M. tuberculosis ESAT-
6/CFP-10 fusion protein were detected in PPD+ and PPD−
groups from an endemic area of Juiz de Fora, Minas Gerais,
Brazil [19]. Herein, the NI group (PPD−) used also lives in
a TB endemic area in Brazil and probably has been exposed
to multiple forms of environmental mycobacteria. However,
to conﬁrm the diagnostic potential of these antigens further
studies using BCG vaccinated controls (PPD+) are required.
Antibodies conventionally are considered to play little
role in defence against mycobacteria, and the function
of antibodies in pathogenesis is yet to be determined.
Macrophages in which mycobacteria resides, and multiply
have high aﬃnity receptors (Fcγ1a n dF c γ3 )f o rI g G 1a n d
IgG3antibodies, andthepresenceofIgG1andIgG3antibod-
ies may enhance bacterial uptake and clearance of pathogen
via the Fc receptor [37]. Hussain et al. [38] reported that
opsonizingantibodiesupregulatemacrophageproinﬂamma-
tory cytokines TNF-α and IL-6 in mycobacterial-stimulated
macrophages thus suggesting a role for this isotype in TB,
since TNF-α synergizes with IFN-γin its tuberculostatic
activity. Since IgG responses against proteins are T cell
dependent, antigen recognition by IgG isotypes implies that
helper T cells also recognize these mycobacterial antigens.
Further, IFN-γ produced by Th1 cells induces murine
IgG2a and IgG2b and human IgG1 and IgG3 [39, 40].Clinical and Developmental Immunology 7
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Figure4:IndividualIFN-γ (a),TNF-α(b),andIL-10(c)productioninresponsetorecombinantAg85A,Ag85B,andESAT-6.Freshlyisolated
PBMC from non-infected individuals (NI), pulmonary TB patients (P), pulmonary TB patients in treatment (PT), and extra-pulmonary
TB (EP) were cultured in the presence of Ag85A (25μg/ml), Ag85B (25μg/ml), PPD (25μg/ml), or ESAT6 (50μg/ml). Supernatants were
harvested after ﬁve days and the cytokines measured by ELISA. Horizontal bars represent mean values. Diﬀerences between responses from
TB patient groups and control groups were analyzed with nonparametric Kruskall-Wallis test. ∗Statistically signiﬁcant diﬀerences in relation
to NI group, (δ)i nr e l a t i o nt oE Pg r o u p ,a n d( # )i nr e l a t i o nt oPg r o u p( P<. 05).8 Clinical and Developmental Immunology
Human IgG1 and IgG3 counterparts of murine IgG2a and
IgG2b share the ability to ﬁx complement and function
as opsonins. In this study, we observed that the increased
IgG1 was coincident with augmented levels of IFN-γ and
TNF-α detected in PBMCs of patients with active TB and
individuals undergoing treatment stimulated with Ag85B
and ESAT-6. These results suggest a possible correlation of
IgG1productionwithTh1andinﬂammatoryresponseinTB.
Interestingly, IL-10 production was elevated only in
patients under treatment in response to Ag85, Ag86, and
ESAT-6. In this study, IL-10 levels could diﬀerentiate indi-
vidualsundergoingchemotherapyfrompulmonaryorextra-
pulmonary patients. Priya et al. [41] have shown that
TB patients from India at the beginning of chemotherapy
produced similar levels of IFN-γ and IL-10 to Ag85A and
the ratio of IFN/IL-10 increases after successful treatment.
Furthermore, Meyaard et al. [42] demonstrated that IL-12 is
able to induce T cells to produce IL-10 and suggest that IL-10
is a negative regulator of IL-12- induced T cell response. In
another study testing TB patients, Priya et al. [43]o b s e r v e d
that high levels of IL-10 detected in active TB decreased in
patients considered cured. These results and our data led us
tohypothesizethatelevatedproductionofIL-10encountered
in PT group is probably a modulatory eﬀect in response to
IL-12 and IFN-γ production and can be associated to the
regulation of immune response.
Th2 responses characterized by inteleukin-4 (IL-4) pro-
duction have been associated with a lack of protection in TB
[44]. In our study, IL-4 levels in response to mycobacterial
recombinant antigens were not detected in all groups
analyzed. These results are in accordance with others that
show that PBMC from TB patients do not produce signif-
icant amounts of IL-4 [45–47]. These results conﬁrm the
polarization of immune response to recombinant antigens to
Th1 proﬁle characterized by the production of high levels of
IFN-γ and TNF-α and no IL-4.
Finally, TB causes a staggering burden of mortality
worldwide, killing an estimated 1.9 million persons annually.
Eﬀective treatment of tuberculosis in developing countries is
hampered by the cost of antituberculosis drugs, inability to
ensure completion of therapy, and rising drug resistant rates.
Vaccination is the most cost-eﬀective strategy to control
and eventual elimination of tuberculosis. The current BCG
vaccine provides some degree of protection against the most
severe manifestations of childhood tuberculosis. However,
protection is incomplete, and BCG vaccine does not reduce
TB rates in adults. In fact, MVA85A, a recombinant modiﬁed
vacciniavirusAnkaraexpressingAg85A,istheﬁrstcandidate
TB subunit vaccine to enter human trials since BCG was
ﬁrst introduced over 80 years ago. More recently, Dissel
et al. [48] demonstrated that vaccination of human na¨ ıve
volunteers with adjuvanted Ag85B-ESAT-6 subunit vaccine
elicited strong antigen-speciﬁc T-cell responses. Since a basic
principle for selecting novel antigen candidates for designing
a TB subunit vaccine is based on their ability to induce
a protective Th1 response [16], our study also conﬁrmed
the value of Ag85A, Ag85B and ESAT-6 as potential vaccine
candidates based upon speciﬁc T cell responses measured by
IFN-γ and TNF-αproduction in all studied patients.
5. Conclusions
Currently, there are no accurate surrogate biomarkers of
protective immunity and diagnoses in TB but clearly host
defense against TB depends critically on Th1 responses
and IFN-γ production. In this study, we have shown
that Ag85A and ESAT-6 are antigens able to diﬀerenti-
ate pulmonary, extra-pulmonary and tuberculosis patients
undergoing chemotherapy from healthy individuals by IFN-
γ production and pulmonary and under treatment patients
from extra-pulmonary TB by TNF-α. Therefore, not only
IFN-γproduction but also TNF-α to Ag85A and ESAT-6
could be used as biomarkers for the clinical status of TB
patients while IL-10 could be useful monitoring TB success-
ful treatment. Finally, the Th1 cytokine proﬁle induced in
PBMC of TB patients by all tested antigens reinforces their
position as potential vaccine candidates.
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